Compare · DXCM vs HAE
DXCM vs HAE
Side-by-side comparison of DexCom Inc. (DXCM) and Haemonetics Corporation (HAE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HAE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 8.7x HAE ($3.40B).
- Over the past year, DXCM is down 10.6% and HAE is up 4.6% - HAE leads by 15.1 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 15 for HAE).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Haemonetics Corporation
- Price
- $76.59+5.15%
- $74.91+4.86%
- Market cap
- $29.57B
- $3.40B
- 1M return
- +25.71%
- +37.96%
- 1Y return
- -10.56%
- +4.58%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 1991
- News (4w)
- 26
- 15
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest HAE
- VP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 259 shares, decreasing direct ownership by 4% to 6,242 units (SEC Form 4) (tax withholding)
- SVP, Human Resources Miller Laurie A. covered exercise/tax liability with 313 shares, decreasing direct ownership by 0.76% to 40,987 units (SEC Form 4) (for withholding tax)
- Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Haemonetics Updates Financial Reporting Segments
- Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by Haemonetics Corporation
- Haemonetics upgraded by BofA Securities with a new price target
- SEC Form 10-K filed by Haemonetics Corporation
- EVP and General Counsel Basil Michelle L covered exercise/tax liability with 2,913 shares and was granted 28,424 shares, increasing direct ownership by 59% to 68,829 units (SEC Form 4) (tax withholding)
- EVP, Chief Operating Officer Chan Frank was granted 27,535 shares and covered exercise/tax liability with 546 shares, increasing direct ownership by 454% to 32,936 units (SEC Form 4) (tax withholding)